Glucagon-like peptide-1 (GLP-1) released from gut enteroendocrine cells controls meal-
related glycemic excursions through augmentation of insulin and inhibition of glucagon …

Background Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved for the
treatment of type 2 diabetes and obesity and elicit robust improvements in glycemic control …

Abstract Glucagon-like peptide-1 (GLP-1) is produced in gut endocrine cells and in the
brain, and acts through hormonal and neural pathways to regulate islet function, satiety, and …

Glucagon-like peptide-1, produced predominantly in enteroendocrine cells, controls glucose
metabolism and energy homeostasis through regulation of islet hormone secretion …

Obesity is a chronic disease associated with increased risk of obesity-related complications
and mortality. Our better understanding of the weight regulation mechanisms and the role of …

The gastrointestinal tract—the largest endocrine network in human physiology—
orchestrates signals from the external environment to maintain neural and hormonal control …

The intestinal epithelium must balance efficient absorption of nutrients with partitioning
commensals and pathogens from the bodies' largest immune system. If this crucial barrier …

The discovery, characterization, and clinical development of glucagon-like-peptide-1 (GLP-
1) spans more than 30 years and includes contributions from multiple investigators, science …

Microbe-derived acetate activates the Drosophila immunodeficiency (IMD) pathway in a
subset of enteroendocrine cells (EECs) of the anterior midgut. In these cells, the IMD …

Incretins are hormones secreted from enteroendocrine cells after nutrient intake that
stimulate insulin secretion from β cells in a glucose‐dependent manner. Glucose …